



Femminella, G. D., Frangou, E., Love, S. B., Busza, G., Holmes, C., Ritchie, C., Lawrence, R., McFarlane, B., Tadros, G., Ridha, B. H., Bannister, C., Walker, Z., Archer, H., Coulthard, E., Underwood, B. R., Prasanna, A., Koranteng, P., Karim, S., Junaid, K., ... Edison, P. (2020). Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). *Trials*, 21(1), [660 (2020)]. <https://doi.org/10.1186/s13063-020-04608-4>

Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
[10.1186/s13063-020-04608-4](https://doi.org/10.1186/s13063-020-04608-4)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the final published version of the article (version of record). It first appeared online via Springer Nature at <https://doi.org/10.1186/s13063-020-04608-4>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

CORRECTION

Open Access



Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)

Grazia Daniela Femminella^{1†}, Eleni Frangou^{2†}, Sharon B. Love², Gail Busza¹, Clive Holmes³, Craig Ritchie¹, Robert Lawrence⁴, Brady McFarlane³, George Tadros⁵, Basil H. Ridha⁶, Carol Bannister⁷, Zuzana Walker⁸, Hilary Archer⁹, Elizabeth Coulthard⁹, Ben R. Underwood¹⁰, Aparna Prasanna¹¹, Paul Koranteng¹², Salman Karim¹³, Kehinde Junaid¹⁴, Bernadette McGuinness¹⁵, Ramin Nilforooshan¹⁶, Ajay Macharouthu¹⁷, Andrew Donaldson¹⁸, Simon Thacker¹⁹, Gregor Russell²⁰, Naghma Malik²¹, Vandana Mate²², Lucy Knight²³, Sajeev Kshemendran²⁴, John Harrison^{25,26}, Christian Hölscher²⁷, David J. Brooks^{1,28}, Anthony Peter Passmore¹⁵, Clive Ballard⁷ and Paul Edison^{1,29*}

Correction to: *Trials* (2019) 20: 191

<https://doi.org/10.1186/s13063-019-3259-x>

After publication of our article [1] the authors have notified us that the name of Prof. Christian Hölscher had been inadvertently forgotten when compiling the list of authors. Dr. Hölscher developed the concept of testing liraglutide in Alzheimer's mouse model, has done the preclinical experiments, and is a co-applicant of the Alzheimer Society UK grant that partially funds the study.

Author details

¹Department of Medicine, Imperial College London, London, UK. ²Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. ³Southern Health NHS Foundation Trust, Havant, UK. ⁴SW London and St George's Mental Health Trust, London, UK. ⁵Aston Medical school, Aston University, Birmingham, UK. ⁶Brighton and Sussex University Hospitals NHS Trust, Brighton, UK. ⁷South London and Maudsley NHS Foundation Trust, London, UK. ⁸University College London and Essex Partnership University NHS

Foundation Trust, Runwell, UK. ⁹North Bristol NHS Trust, Bristol, UK. ¹⁰Cambridgeshire and Peterborough NHS Foundation Trust, Peterborough, UK. ¹¹Black Country Partnership NHS Foundation Trust, West Bromwich, UK. ¹²Northamptonshire Healthcare NHS Foundation Trust, Kettering, UK. ¹³Lancashire Care NHS Foundation Trust, Preston, UK. ¹⁴Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, UK. ¹⁵Centre for Public Health, Queen's University Belfast, Belfast, UK. ¹⁶Surrey and Borders Partnership NHS Foundation Trust, Leatherhead, UK. ¹⁷NHS Ayrshire and Arran, Crosshouse, UK. ¹⁸NHS Lanarkshire, Glasgow, UK. ¹⁹Derbyshire Healthcare NHS Foundation Trust, Derby, UK. ²⁰Bradford District Care NHS Foundation Trust, Bradford, UK. ²¹5 Boroughs Partnership NHS Foundation Trust, Warrington, UK. ²²Cornwall Partnership NHS Foundation Trust, Redruth, UK. ²³Somerset Partnership NHS Foundation Trust, Bridgwater, UK. ²⁴South Staffordshire and Shropshire Healthcare NHS Foundation Trust, Stafford, UK. ²⁵Alzheimer Center VUmc Amsterdam, Amsterdam, the Netherlands. ²⁶Institute of Psychiatry, Psychology & Neuroscience King's College London, London, UK. ²⁷Research Department, Henan University of Chinese Medicine, Zhengzhou, China. ²⁸Newcastle University, Newcastle upon Tyne, UK. ²⁹School of Medicine, College of Biomedical and Life sciences, Cardiff University, Cardiff CF14 4YS, UK.

The original article can be found online at <https://doi.org/10.1186/s13063-019-3259-x>.

* Correspondence: paul.edison@imperial.ac.uk

[†]Grazia Daniela Femminella and Eleni Frangou contributed equally to this work.

¹Department of Medicine, Imperial College London, London, UK

²⁹School of Medicine, College of Biomedical and Life sciences, Cardiff University, Cardiff CF14 4YS, UK

Full list of author information is available at the end of the article

Published online: 19 July 2020

Reference

1. Femminella, et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). *Trials*. 2019;20:191. <https://doi.org/10.1186/s13063-019-3259-x>.



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.